Literature DB >> 20171194

Inhibition of calcium-independent phospholipase A2 activates p38 MAPK signaling pathways during cytostasis in prostate cancer cells.

Bin Sun1, Xiaoling Zhang, Christopher Yonz, Brian S Cummings.   

Abstract

The p38 mitogen-activated protein kinase (MAPK) signaling pathways activated during cytostasis induced by Ca(2+)-independent phospholipase A2 (iPLA2) inhibition in prostate cancer cells were investigated. iPLA2 inhibition using siRNA, or the selective inhibitor bromoenol lactone (BEL) and it's enantiomers, decreased growth in LNCaP (p53 positive) and PC-3 (p53 negative) human prostate cancer cells. Decreased cell growth correlated to time- and concentration-dependent activation of the mitogen-activated protein kinase p38 in both cell lines. Inhibition of cytosolic iPLA(2)beta using S-BEL, induced significantly higher levels of P-p53, p53, p21 and P-p38 expression than inhibition of microsomal iPLA2 gamma using R-BEL. Inhibition of p38 using SB202190 or SB203580 inhibited BEL-induced increases in P-p53 (ser15), p53 and p21, and altered the number of cells in G1 in LNCaP cells, and S-phase in PC-3 cells. BEL treatment also induced reactive species in PC-3 and LNCaP cells, which was partially reversed by pretreatment with N-acetyl-cysteine (NAC). NAC subsequently inhibited BEL-induced activation of p38 and p53 in LNCaP cells. In addition, treatment of cells with NAC partially reversed the effect of BEL on cell growth and preserved cell morphology. Collectively, these data demonstrate the novel findings that iPLA2 inhibition activates p38 by inducing reactive species, and further suggest that this signaling kinase is involved in p53 activation, cell cycle arrest and cytostasis. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20171194     DOI: 10.1016/j.bcp.2010.02.005

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  17 in total

Review 1.  Phospholipase A2 enzymes: physical structure, biological function, disease implication, chemical inhibition, and therapeutic intervention.

Authors:  Edward A Dennis; Jian Cao; Yuan-Hao Hsu; Victoria Magrioti; George Kokotos
Journal:  Chem Rev       Date:  2011-09-12       Impact factor: 60.622

2.  Platelet-activating factor and metastasis: calcium-independent phospholipase A2β deficiency protects against breast cancer metastasis to the lung.

Authors:  Jane McHowat; Gail Gullickson; Richard G Hoover; Janhavi Sharma; John Turk; Jacki Kornbluth
Journal:  Am J Physiol Cell Physiol       Date:  2011-01-12       Impact factor: 4.249

3.  The involvement of FBP1 in prostate cancer cell epithelial mesenchymal transition, invasion and metastasis by regulating the MAPK signaling pathway.

Authors:  Yan-Ping Zhang; Kai-Long Liu; Zhan Yang; Bao-Sai Lu; Jin-Chun Qi; Zhen-Wei Han; Yue-Wei Yin; Ming Zhang; De-Min Chen; Xiao-Wei Wang; Wei Li; Hong Xin
Journal:  Cell Cycle       Date:  2019-08-25       Impact factor: 4.534

4.  Enhanced antitumor activity of low-dose continuous administration schedules of topotecan in prostate cancer.

Authors:  Ibrahim A Aljuffali; Jason N Mock; Leah J Costyn; Ha Nguyen; Tamas Nagy; Brian S Cummings; Robert D Arnold
Journal:  Cancer Biol Ther       Date:  2011-09-01       Impact factor: 4.742

5.  Group VIA PLA2 (iPLA2β) is activated upstream of p38 mitogen-activated protein kinase (MAPK) in pancreatic islet β-cell signaling.

Authors:  Haowei Song; Mary Wohltmann; Min Tan; Shunzhong Bao; Jack H Ladenson; John Turk
Journal:  J Biol Chem       Date:  2011-12-22       Impact factor: 5.157

Review 6.  Calcium-independent phospholipases A2 and their roles in biological processes and diseases.

Authors:  Sasanka Ramanadham; Tomader Ali; Jason W Ashley; Robert N Bone; William D Hancock; Xiaoyong Lei
Journal:  J Lipid Res       Date:  2015-05-28       Impact factor: 5.922

7.  Haloenol pyranones and morpholinones as antineoplastic agents of prostate cancer.

Authors:  Jason N Mock; John P Taliaferro; Xiao Lu; Sravan Kumar Patel; Brian S Cummings; Timothy E Long
Journal:  Bioorg Med Chem Lett       Date:  2012-05-17       Impact factor: 2.823

Review 8.  Prostate cancer chemoprevention in men of African descent: current state of the art and opportunities for future research.

Authors:  Ganna Chornokur; Nagi B Kumar
Journal:  Cancer Causes Control       Date:  2013-06-05       Impact factor: 2.506

9.  Dual specificity phosphatase 1 expression inversely correlates with NF-κB activity and expression in prostate cancer and promotes apoptosis through a p38 MAPK dependent mechanism.

Authors:  Beatriz Gil-Araujo; María-Val Toledo Lobo; María Gutiérrez-Salmerón; Julia Gutiérrez-Pitalúa; Santiago Ropero; Javier C Angulo; Antonio Chiloeches; Marina Lasa
Journal:  Mol Oncol       Date:  2013-09-14       Impact factor: 6.603

10.  Expression and clinical significance of the nin one binding protein and p38 MAPK in prostate carcinoma.

Authors:  Jian-Ping Che; Wei Li; Yang Yan; Min Liu; Guang-Chun Wang; Qian-Yu Li; Bin Yang; Xu-Dong Yao; Jun-Hua Zheng
Journal:  Int J Clin Exp Pathol       Date:  2013-10-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.